Moderna rises after earnings as vaccine sales lift its outlook
Earnings results
- EPS
Reported profit of $0.38 per share versus a $0.51 loss a year earlier.
- Revenue
$1.31 billion, up 29% from a year earlier.
- Guidance raised
Moderna expects 15% to 25% sales growth this year, up from a forecast of up to 10%.
Earnings and the stock move
Moderna shares rose after the company posted a quarterly profit and raised its 2026 revenue growth forecast. International COVID vaccine deliveries supported sales, while lower research spending helped the company turn a profit.
Q3 2026 earnings recap
Moderna rose about 10% during trading on November 6, 2026, after it returned to a quarterly profit and raised its sales outlook.
- September-quarter revenue rose 29% to $1.31 billion. Higher COVID vaccine sales outside the U.S. drove most of the growth.
- Moderna earned $0.38 per share, compared with a $0.51 loss per share a year earlier.
- Management expects revenue to grow 15% to 25% this year, up from a forecast of up to 10%.
- Research and development spending fell 27% in the quarter as several late-stage infectious disease studies wrapped up or wound down.
- Cash and investments reached $8 billion at the end of September. New debt helped lift the balance.
- Moderna reported positive late-stage results for its personalized melanoma treatment with Merck. Commercial sales would depend on regulatory approval.
Watch whether vaccine demand holds and Moderna can turn its cancer research into a new source of revenue.
Financials and technicals
Charts through Nov 5, 2026. The session move above may reflect later news.
Technical setup and risks
The November 5 close was about $241. A regular close above $261 would clear the prior two session highs. A drop below $238 would break Thursday’s low.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.
